The safety of anidulafungin
- José A. Vazquez(corresponding author)
- Wayne State University,
- Henry Ford Health System
Abstract
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 751-758 (8 pages)Journal (Volume, Issue Number)
Expert Opinion on Drug Safety (Volume 5, Issue 6)Publication milestones
- Published - 11/2006
Publication status
ISSN
1474-0338Publication IDs
- Scopus: 33750553597
- PubMed: 17044802
